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We performed observational multicenter study on  CKD patients in stage 3-5, with renal anemia. Key inclu-
sion criteria were: haemoglobin level > 6.0 g/dL, age >18 years and written inform consent. Exclusion criteria 
were dialysis and transplanted patients and haemoglobin level > 12.0 g/dL. Study was performed from 2006.-
2012. and 368 patients were included. All patients received Erythropoietin beta (Neorecormon®; Roche, 
Basel, Switzerland) subcutaneously in dose of 4000-6000 IU every week during the correction phase of ane-
mia treatment or once weekly 2000-4000IU during the maintenance treatment. Iron supplementation was 
administrated orally in >80% patients in order to achieve serum ferritin 200-500 µg/L. From 368 patients on 
beginning, 246 were followed and statistically analyzed (M:F=136/110). Mean duration study period was 13.6 
(Std.dev.10.36) months (max 52 months). Patients were mainly men (55.3%), age >51 years (81.3%). The me-
dian of Hb level at baseline was 9.35 g/dL and after 12 months 10.4 g/dL respectively. After 12 months, most 
of patients had Hb range 10.0 g/dL to 11.0 g/dL. There were no statistically significant differences between 
Hb in groups of patients stratified according to the primary kidney disease and age, and between sex: mean 
level of Hb in M at the end of study was 10.27 g/dl and  in F 10.58 g/dl (p=0.051). Baseline eGFR (Cocroft 
Gault) values were 16.31 (range form 4.1-62.6) vs. 16.71 (range from 4.9-43.8) mL/min after 12 months.  The 
majority of patients had reported better exercise tolerance and sleep. 47.7% of patients have started after 
predialysis education with dialysis and in 2 patients preemptive transplantation was performed. The results 
of this multicenter observational study in Croatia suggest that the use of erythropoietin beta  is effective and 
safe in correction of anemia in pre-dialysis CKD patients.
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INTRODuCTION
Anemia is a common complication of patients with 
chronic kidney disease (CKD), which lowers their qual-
ity of life and causes cardiovascular diseases such as 
congestive heart failure and coronary heart disease, and 
accelerates the progression of kidney dysfunction(1-2). 
Anemia is a decrease in the effective circulating volume 
of red blood cells and is measured by serum hemoglobin 
(Hb). The World Health Organization (WHO) defines 
anemia as Hb <13.0 g/dl in adult men and non-menstru-
ating women and <12.0 g/dl in menstruating women(3). 
The data from the uS Renal Data System (uSRDS) have 
shown that the prevalence of anemia is 4.3% in the gen-
eral population, while patients with a glomerular filtra-
tion rate (GFR) <60ml/minute showed an average preva-
lence of 14.2%, with escalating prevalence of anemia 
with progression through stages of CKD: 6.2% in stages 
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1 and 2, 11.9% at stage 3, and from 47.8% to 95% in stag-
es 4 and 5(4,5). Symptoms generally occur when the Hb 
level is less than 10.0 g/dl and become more pronounced 
as Hb continues to decline(6-9). The cause of anemia in 
CKD is often multifactorial, with the most common 
etiology being ineffective erythropoietin (EPO) produc-
tion by the diseased kidneys, often complicated by iron 
deficiency(10). There are other factors contributing to 
anemia in patients with CKD, such as acute and chronic 
inflammation and the accumulation of uremic toxins, 
but will not be the focus of this article. Recombinant hu-
man erythropoietin was introduced in the 1980s in the 
treatment of anemia associated with CKD. The majoritiy 
of the trials and evidence for use of ESAs in the CKD 
population was with patients on hemodialysis and have 
documented an improved QoL and functional status, as 
well as relief of symptoms associated with anemia(11-13). 
Pre-dialyzed patients in Croatia can not afford the treat-
ment with erythropoietin. Purpose of this Study was to 
evaluate efficacy and safety of erythropoietin adminis-
tration subcutaneously once weekly for correcting ane-
mia in the patients in Croatia with chronic kidney dis-
ease (CKD), not on dialysis.
PATIENTS AND METHODS
Study Design and Patients
This retrospective observational study was conducted in 
pre-dialyzed Croatian nephrology  centers for follow-up 
of patient records. Records of CKD pre-dialyzed patients 
who were included in the ML20474 STuDY database 
between May 2006 and February 2012 were analyzed if 
they had at least one Hb value per month over a period of 
at least two months. Key inclusion criteria were: haemo-
globin level > 6.0 g/dL, age >18 years and written inform 
consent. Exclusion criteria were dialysis and transplant-
ed patients and haemoglobin level >12.0 g/dL, patients 
with cancer, chronic infectious disease (such as hepatitis 
B, C or HIV infection). On beginning 368 patients were 
included. All patients received Erythropoietin beta (Ne-
orecormon®; Roche, Basel, Switzerland) subcutaneously 
in dose of 4000-6000 Iu every week during the correc-
tion phase of anemia treatment (Hb value  above 9.0-10.0 
g/dL) or once weekly 2000-4000 Iu during the main-
tenance treatment. Oral iron supplementation was ad-
ministrated in patients in order to achieve serum ferritin 
200-500 mg/L. Other medical treatment and diagnostic 
monitoring were left to the Centers’ discretion following 
their routine practice.
The main objective of the study was the description of 
the therapeutic anemia management in pre-dialyzed 
patients in Croatia. Secondary objectives included a de-
scription of the used treatment strategies in comparison 
to national and international guidelines  compared  to 
target Hb levels.
Data collection 
Anonymized data on sex, height, weight, underlying 
disease causing chronic kidney disease, glomerular 
filtration rate, co-morbidities (diabetes, hypertension), 
laboratory tests for anemia (complete blood count, Hb, 
serum ferritin, serum iron, transferrin saturation), C-
reactive protein, serum albumin, serum creatinine, urea, 
potassium, treatments of anemia (transfusions, ESA, 
iron) and significant events such as hospitalizations and 
death were extracted from the database for 246 CKD 
pre-dialysis patients. 
Statistical Analysis
No formal statistical hypothesis was tested. The sta-
tistical analysis was essentially descriptive (percent-
ages, mean and standard deviation [SD], median  range). 
Groups were compared using Student’s t-test for quanti-
tative variables and Chi-2 test for qualitative variables. 
All tests were considered statistically significant if p < 
0.05. Statistical analysis was performed using STATIS-
TICA 10, 2011 software (Stat Soft Inc., uSA).
RESuLTS 
Primary purpose of this Study was to evaluate efficacy 
and safety of erythropoietin administration subcutane-
ously once weekly for correcting anemia in the patients 
in Croatia with chronic kidney disease (CKD), not on 
dialysis. This study in a cohort of 246 CKD pre-dialyzed 
patients (M:F=136/110) showed that 55.3%  (M=136) of 
evaluable patients were male.  The median age was 65.5, 
ranging from 19-91 years. The majority of patients (51.6%, 
127 of 246) were in the age group of 51-75 years. Patients 
older than 75 years accounted for a significant proportion 
(29.7%, 73 of 246). Mean duration study period was 13.6 
(SD 10.36) months (max 52 months). 
The most common causes of primary renal disease were 
hypertensive renal disease (hypertensive nephrosclerosis 
in 31.3%, 77 pt) and diabetic nephropathy (27.6%, 68 pt), 
whereas chronic pyelonephritis and glomerulonephritis have 
been causes of primary renal disease in 48 (19, 5%) and 28 
(11.4%) patients. Other causes of CKD accounted for 8.5%. 
It lacked data on underlying disease in 1.6% (4 patients). The 
largest number of patients (54.1%) had 3 or more concurrent 
diseases, while 45.9% had 2 or more accompanying diseases 
such as  hypertension, diabetes and atrial fibrillation.
The median of Hb level at baseline was 9.35 g/dL (SD 10.76) 
and after 12 months 10.4 g/dL respectively. After 12 months, 
most of patients had Hb range above 10.0 g/dL. There were 
no statistically significant differences between Hb in groups 
of patients stratified according to the primary kidney dis-
ease and age, and between sex: mean level of Hb in M at the 
end of study was 10.27 g/dl and  in F 10.58 g/dl (p=0.051). 
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The majority of patients prior to study entry did not treat 
anemia. Only 18.3% of patients received an oral iron 
therapy (100 mg). During the study 80% of patients were 
treated with oral  iron (ferrous sulfate tablets 200 mg) 
with ESA supplemented and this was the most frequent-
ly used anemia treatment option.
Average iron value was 8.94 umol/L, (range 2-24.9), and 
the average ferritin value (only the part of the patient 
that is determined by ferritin) was 285.7 mg/L. Most pa-
tients were within 3/4 CKD stage (81.5%). The levels of 
hemoglobin (Hb) less than 9.0 g/dL had 35% of patients 
at baseline, while at the end of the study only 10.6%. At 
the end of the study 89.4% of patients achieved a level of 
hemoglobin (Hb) above 9.0 g/dL. 
Weekly doses of  NeoRecormon varied at the start and 
at the end of treatment: at baseline over 50% of patients 
required a week of dose administration of 4000-6000 Iu 
sc. Theere were about 17% requiring a higher dose of 
6000 Iu sc. weekly. At the end of follow-up only 6.5% 
of patients required a dose higher than 6000 Iu sc (2.5 
x times less than at the beginning of the study). At the 
end of the study there was an increase in the number of 
patients with application of a lower doses of 4000 Iu sc. 
weekly. Analysis of variance (ANOVA) showed that the 
values  of Hb at baseline were statistically significantly 
lower than the value at the end of the Hb monitoring for 
all weekly dosage (p<0,05) (Figure 1).
Secondary endpoint of study was evaluation  of impact 
of anemia on improvement of kidney function: Renal 
function after 6 months of treatment of anemia rema-
ins stable. Baseline eGFR (Cockroft-Gault) values were 
16.31 (range from 4.1-62.6) vs. 16.71 (range from 4.9-
43.8) mL/min after 12 months and statistically proven 
to improve renal function compared to baseline  after 6 
months (p <0.05) (Table 1). During the study 9 patients 
(3.7%) died and 2 (1F/1M) received a preemptive kidney 
transplant. We do not consider 9 deaths related to admin-
istration of NeoRecormon. After predialysis education 
47.7% of patients have started with dialysis.
DISCuSSION
Chronic kidney disease (CKD) is a major global health 
problem and anemia is a frequent complication. Anemia 
may, if there is no proteinuria, be the first sign of kidney 
disease. In all patients with anemia and CKD diagnostic 
evaluation is required. Prior to diagnose a renal ane-
mia, it is necessary to eliminate possible other causes. 
The cause of anemia is often multifactorial in patients 
with CKD. After controversy about the optimal (up-
per) limit of Hb levels based on three studies in patients 
with CKD not on dialysis, comparing ESA treatment 
with high Hb target levels (≥13 g/dL) vs. low Hb targets 
(~11 g/dL) or placebo (CHOIR, CREATE and TREAT 
study),  European guidelines for ESA-treated dialysis 
and non-dialysis patients recommend Hb target levels 
in the range of 10–12 g/dL(6,12). The guidelines provided 
by KDIGO recommended Hb target from 9.5 to 11.5 g/
dL(8). Hb levels should not exceed 12 g/dL, particularly 
in patients with severe cardiovascular disease or diabe-
tes and concurrent peripheral vascular disease(8,12).
Hb=hemoglobin value  (g/L), Fe= iron (umol/L), 
creatinine = serum value (IDMS standardization, umol/l)
GFR=glomerular filtration rate (CG/Cockroft-Gault, ml/min), 
Values are expressed as mean  standard deviation (SD). Other data are presented as number
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Descriptive Statistics  
Variables Valid N Mean Minimum Maximum Std.Dev. 
Hb beginning (month1) 243 93.50 61.0 123.0 10.757 
Hb end (month 12) 239 104.23 59.0 134.0 12.037 
Fe  beginning 202 8.94 2.0 24.9 3.775 
Creatinine (month 1) 243 383.33 107.0 1300.0 171.302 
Creatinine (month 12) 113 377.99 141.0 820.0 171.164 
GFR  (month 1) 235 16,31 4,1 62,6 8,638 
GFR  (month 12) 112 16,71 4,9 43,8 9,042 
 
Hb=hemoglobin value (g/L), Fe= iron (umol/L),  
creatinine = serum value (IDMS standardization, umol/l) 
GFR = glomerular filtration rate (CG/Cockroft-Gault, ml/min) 
Values are expressed as mean standard deviation (SD) 
Other data are presented as number 
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Croatian Society of Nephrology, Dialysis and Trans-
plantation (HDNDT) has already published its own 
guidelines based on the recommendations and the posi-
tive experience of European and international profes-
sional societies, as well as on own experience.
To the best of our knowledge, this is the first multicen-
tar report of beneficial treatment in CKD pre-dialyzed 
patient in Croatia. However, our  data show additional 
effect of anemia treatment  in slowing natural progres-
sion of CKD. As expected, most patients of our study 
were treated with an ESA and/or  iron to control anemia. 
CONCLuSIONS
Anemia is independent risk factor for kidney disease 
progression and recognition of the appropriate treatment 
is essential for providing renoprotection.
The results of this multicenter observational study in 
Croatia suggest that the use of erythropoietin beta  is 
effective and safe in correction of anemia in pre-dialysis 
CKD patients.
Conflict of Interest: None to declare.
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In the majority of patients Hb levels were in the novel Hb 
target range of 10–11 g/dL and was within the acceptable 
today target range according to European guidelines.
Further research documenting the frequency and in-
vestigating the mechanisms of those effects reported 
in CKD pre-dialysed patients  with long lasting  is 
necessary, as treatment of anamia in pre-dialysed pa-
tients  may constitute an effective treatment option 
to reduce cardiovascular risk and kidney failure pro-
gression and prepare patients for preemptive kidney 
transplantation.
Figure 1.
Levels of Hemoglobin  and EPO doses during the study
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Prikazano je prospektivno, neintervencijsko, opservacijsko praćenje učinkovitosti i podnošljivosti eritropoeti-
na beta (NeoRecormon®) u liječenju anemije u bolesnika s  kroničnom  bubrežnom bolesti (KBB) koji još nisu 
podvrgnuti nadomjestnom bubrežnom liječenju u Hrvatskoj. U studiji ML20474 uključeno je ukupno 368 bole-
snika u 3 do 5. stadiju KBB s anemijom u kojih je bilo indicirana primjena lijekova koji stimuliraju eritropoezu 
(LSE). Svi su bolesnici primili eritropoetin beta (Neorecormon) supkutano u dozi od 4000 do 6000 IU jednom 
tjedno u razdoblju do korekcije anemije ili porasta Hb za 10 g/L a potom jednom tjedno u reduciranoj dozi od 
50% u odnosu na početnu. Bolesnici su praćeni u razdoblju od 3 do maksimalno 52 mjeseca, prosječno 13.6 
(Std.dev.10,36) mjeseci. Većina bolesnika bili su muškarci (55,3%), dob preko 51 godina (81,3%). Medijan 
vrijednosti razine hemoglobina iznosio je 93.5 g/L na početku studije a nakon 12 mjeseci  104,23 g/L. Nije 
bilo statistički značajne razlike u razini Hb ovisno o uzroku osnovne bubrežne bolesti i dobi bolesnika. Na 
kraju praćenja većina je bolesnika navela bolje podnošenje napora, bolje spavanje i manju razdražljivost. 
Nuspojave primjene terapije eritropoetinom beta nismo uočili. Rezultati pokazuju da je primjena učinkovita i 
sigurna u liječenju anemije u bolesnika s KBB koji nisu započeli liječenje nadomještanjem bubrežne funkcije. 
Ključne riječi: anemija, kronična bolest bubrega
